ANEBULO PHARMAC. DL-,001ANEBULO PHARMAC. DL-,001ANEBULO PHARMAC. DL-,001

ANEBULO PHARMAC. DL-,001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪72.40 M‬EUR
−0.38EUR
‪−10.76 M‬EUR
‪9.28 M‬
Beta (1Y)
−0.93

About Anebulo Pharmaceuticals, Inc.

CEO
Richard Anthony Cunningham
Headquarters
Lakeway
Employees (FY)
2
Founded
2020
FIGI
BBG01199R2D9
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, ANEB-001, is currently in phase two of trial. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ANEBULO PHARMAC. DL-,001 stocks are traded under the ticker 214.
ANEBULO PHARMAC. DL-,001 is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
214 earnings for the last quarter are −0.10 EUR per share, whereas the estimation was −0.09 EUR resulting in a −10.00% surprise. The estimated earnings for the next quarter are −0.11 EUR per share. See more details about ANEBULO PHARMAC. DL-,001 earnings.
ANEBULO PHARMAC. DL-,001 revenue for the last quarter amounts to 0 EUR despite the estimated figure of 0 EUR. In the next quarter revenue is expected to reach 0 EUR.
Yes, you can track ANEBULO PHARMAC. DL-,001 financials in yearly and quarterly reports right on TradingView.
214 net income for the last quarter is ‪−2.46 M‬ EUR, while the quarter before that showed ‪−2.35 M‬ EUR of net income which accounts for −4.91% change. Track more ANEBULO PHARMAC. DL-,001 financial stats to get the full picture.
No, 214 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 214 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ANEBULO PHARMAC. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
214 reached its all-time high on Mar 15, 2022 with the price of 6.90 EUR, and its all-time low was 1.72 EUR and was reached on Dec 15, 2023. View more price dynamics on 214 chart.
See other stocks reaching their highest and lowest prices.
As of May 12, 2024, the company has 2.00 employees. See our rating of the largest employees — is ANEBULO PHARMAC. DL-,001 on this list?
We've gathered analysts' opinions on ANEBULO PHARMAC. DL-,001 future price: according to them, 214 price has a max estimate of 7.50 EUR and a min estimate of 3.75 EUR. Watch 214 chart and read a more detailed ANEBULO PHARMAC. DL-,001 stock forecast: see what analysts think of ANEBULO PHARMAC. DL-,001 and suggest that you do with its stocks.